BGHL (GBP): NAV(s)                        

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
50
BGHL (GBP): NAV(s)

                                       BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 

Close of business 12 Jul 2017.

 

Estimated NAV

 

  Euro Shares Sterling Shares
Estimated NAV €  23.6567 £  20.8202
Estimated MTD return  -0.39 %  -0.39 %
Estimated YTD return  6.83 %  7.10 %
Estimated ITD return  136.57 %  108.20 %

 

NAV and returns are calculated net of management and performance fees

 

Market information

 

Euro Shares Amsterdam (AEX) London (LSE)
Market Close €  19.70 N/A
Premium/discount to estimated NAV  -16.73 % N/A
     
Sterling Shares Amsterdam (AEX) London (LSE)
Market Close N/A GBX 1,655.00
Premium/discount to estimated NAV N/A  -20.51 %

 

 

Transactions in own securities purchased into treasury

 

Ordinary Shares Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A
Range of Price N/A N/A

           

                                           

Liquidity Enhancement Agreement Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A

 

BGHL Capital

 

BGHL Ordinary Shares Euro Shares Sterling Shares
Shares Outstanding  28,862,115  528,912
Held in treasury N/A N/A
Shares Issued  28,862,115  528,912

 

Estimated BG Fund NAV

Class B Euro Shares (estimated) €  187.7353

 

The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.

 

For further information please contact:

Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com

 

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

                all investment is subject to risk;

                results in the past are no guarantee of future results;

                the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and

                if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

 

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

 

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...898f8bfbee

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Rate and Betterment's Mortgage Play: Savings or Spin?

Updated Category News Views 151

So here’s the scoop: Rate just teamed up with Betterment on February 17, 2026, offering some pretty slick mortgage incentives for those sitting on at least $100K in their investment accounts. But let’s dig into the nitty-gritty before you start dreaming of that low-rate home loan. Betterment's Strategy: Solid Gains or Hype? The partnership aims to deliver discounted...

Continue Reading
UK Water Companies Gain Confidence After Regulatory Update

Updated Category News Views 253

Morgan Stanley Highlights UK Water Sector Improvements Investment risks surrounding listed UK water companies have significantly decreased following a key regulatory decision concerning water bill increases in England and Wales. According to analysts from Morgan Stanley, this development has created a more favorable landscape for investors in the sector. Key Insights From...

Continue Reading
SiLC Technologies Unveils Advanced Eyeonic Trace Scanner

Updated Category News Views 228

SiLC Technologies Introduces Eyeonic Trace Laser Line Scanner SiLC Technologies, a leader in the development of advanced integrated FMCW LiDAR solutions, recently announced an exciting new product: the Eyeonic Trace Laser Line Scanner. This state-of-the-art Class 1 Laser Line Scanner is engineered to achieve precise measurements of objects from distances of up to 10...

Continue Reading
Accord BioPharma Launches HERCESSI™ for Cancer Treatment

Updated Category News Views 94

Accord BioPharma Announces FDA Approval for HERCESSI™ Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has achieved a major milestone in cancer treatment with the FDA's approval of a new 420mg strength of HERCESSI™ (trastuzumab-strf). This biosimilar to Herceptin (trastuzumab) targets different types of HER2-overexpressing cancers, such as...

Continue Reading
Why Oklo Stock is Soaring This Week and What to Expect

Updated Category News Views 493

What’s Driving Oklo Inc’s Stock Surge? Oklo Inc (NYSE: OKLO) is making waves in the stock market as its shares witness impressive growth. Over the past month, the company has experienced a remarkable rally of approximately 60%. Investors are keen to learn about the driving forces behind this upward trend. Recent Positive Developments This recent surge can primarily be...

Continue Reading